Document is current
Any future updates will be listed below
-
Authors
Parodis, Ioannis https://orcid.org/0000-0002-4875-5395
Rovin, Brad H. https://orcid.org/0000-0001-5639-0210
Tektonidou, Maria G. https://orcid.org/0000-0003-2238-0975
Anders, Hans-Joachim https://orcid.org/0000-0003-2434-2956
Malvar, Ana https://orcid.org/0000-0003-1609-3857
Mok, Chi Chiu https://orcid.org/0000-0003-3696-1228
Mohan, Chandra
- License Information
-
More Information
Article History
Accepted: 20 August 2025
First Online: 25 September 2025
Competing interests
: I.P. has received research funding and/or honoraria from Amgen, AstraZeneca, Aurinia, BMS, Elli Lilly, Gilead, GSK, Janssen, Novartis, Otsuka and Roche. B.H.R. has received funding from Biogen and consultancy fees from Alexion, Vera, Roche/Genentech, AstraZeneca, GSK, Kyverna, Artiva, Aurinia, Novartis, Biogen, Sana, Otsuka, Kezar and HiBio. M.G.T. has received research funding and/or honoraria from Abbvie, BMS, DEMO, GSK, Lilly, Novartis and UCB. H.-J.A. has received funding from Boehringer-Ingelheim and consultancy fees from Novartis, AstraZeneca, Bayer, Boehringer-Ingelheim, Vifor, Otsuka, Roche and Lilly, as well as payments from the European Renal Association for his role as Editor-in-Chief of Nephrology Dialysis Transplantation. H.-J.A. is a member of the Western-European Regional board of the International Society of Nephrology (ISN). A.M. serves as a board member and/or consultant for Roche, BMS, GSK, Kezar, Biogen, Genentech, Novartis and Pfizer. C.M. has received consultancy fees or sponsored research agreement or equity from Boehringer-Ingelheim, Equillium, Progentec Diagnostics and Voyager Therapeutics. C.M. is on the Medical Scientific Advisory Council of the Lupus Foundation of America. C.C.M. declares no competing interests.
